Javascript must be enabled to continue!
Biodistribution and Targeted Antitumor Effects of Trastuzumab-Modified Gold Nanorods in Mice with Gastric Cancer
View through CrossRef
Background and Objectives:
Targeted drug is often engulfed and cleared by the reticuloendothelial
system in vivo, resulting in reduced treatment efficacy. This study aimed to explore the biodistribution
and HER-2-targeted antitumor effects of trastuzumab-modified gold nanorods (Tra-AuNRs) in
a gastric cancer animal model.
Methods:
Gold nanorods were synthesized using a seed-mediated growth method, and then subjected to
trastuzumab-targeted modification. Elemental analysis, Fourier transform infrared spectroscopy, and Xray
photoelectron spectroscopy were performed; UV-visible absorption peak, photothermal effects,
morphology, and size distribution of Tra-AuNRs were characterized. The targeted killing effect of Tra-
AuNRs on gastric cancer cells was assessed in vitro. Tra-AuNRs were injected intravenously and intratumorally
into gastric cancer-bearing nude mice in vivo and their distribution was detected. Tumor
growth inhibition rate and tumor apoptosis-related protein expression were compared between groups.
Results:
Tra-AuNRs presented a relatively uniform morphology with an average particle size of 59.9
nm and a longitudinal plasmon resonance absorption peak of 790 nm. The targeted killing rate of gastric
cancer cells in vitro by Tra-AuNRs was 87.9%. After intravenous injection, Tra-AuNRs were mainly
distributed in the liver, tumor, spleen, and lungs. Comparatively, Tra-AuNRs were mainly distributed
in the tumor when intratumorally injected, with a tumor concentration of 6.42 μg/g after 24 h. The tumor
growth inhibition rate reached 78.3% in the intratumoral injection group, with significantly higher
BAX, BAD, and CASPASE-3 expression than that in the intravenous injection group.
Conclusion:
The findings suggest that Tra-AuNRs can be used for HER-2-positive gastric cancer
treatment. Intratumoral injection of Tra-AuNRs significantly increased the local tumor drug concentration
and improved the molecular targeted antitumor growth effect in gastric cancer-bearing nude mice.
Bentham Science Publishers Ltd.
Title: Biodistribution and Targeted Antitumor Effects of Trastuzumab-Modified
Gold Nanorods in Mice with Gastric Cancer
Description:
Background and Objectives:
Targeted drug is often engulfed and cleared by the reticuloendothelial
system in vivo, resulting in reduced treatment efficacy.
This study aimed to explore the biodistribution
and HER-2-targeted antitumor effects of trastuzumab-modified gold nanorods (Tra-AuNRs) in
a gastric cancer animal model.
Methods:
Gold nanorods were synthesized using a seed-mediated growth method, and then subjected to
trastuzumab-targeted modification.
Elemental analysis, Fourier transform infrared spectroscopy, and Xray
photoelectron spectroscopy were performed; UV-visible absorption peak, photothermal effects,
morphology, and size distribution of Tra-AuNRs were characterized.
The targeted killing effect of Tra-
AuNRs on gastric cancer cells was assessed in vitro.
Tra-AuNRs were injected intravenously and intratumorally
into gastric cancer-bearing nude mice in vivo and their distribution was detected.
Tumor
growth inhibition rate and tumor apoptosis-related protein expression were compared between groups.
Results:
Tra-AuNRs presented a relatively uniform morphology with an average particle size of 59.
9
nm and a longitudinal plasmon resonance absorption peak of 790 nm.
The targeted killing rate of gastric
cancer cells in vitro by Tra-AuNRs was 87.
9%.
After intravenous injection, Tra-AuNRs were mainly
distributed in the liver, tumor, spleen, and lungs.
Comparatively, Tra-AuNRs were mainly distributed
in the tumor when intratumorally injected, with a tumor concentration of 6.
42 μg/g after 24 h.
The tumor
growth inhibition rate reached 78.
3% in the intratumoral injection group, with significantly higher
BAX, BAD, and CASPASE-3 expression than that in the intravenous injection group.
Conclusion:
The findings suggest that Tra-AuNRs can be used for HER-2-positive gastric cancer
treatment.
Intratumoral injection of Tra-AuNRs significantly increased the local tumor drug concentration
and improved the molecular targeted antitumor growth effect in gastric cancer-bearing nude mice.
Related Results
Abstract 1737: Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib
Abstract 1737: Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib
Abstract
Overexpression of HER2 is seen in 15-20% of breast cancer and is a predictor of poor prognosis. Trastuzumab, a monoclonal antibody to the ECD of the HER2 re...
Abstract PO5-07-11: Use of 64Cu-DOTA trastuzumab -PET to predict response to trastuzumab-deruxtecan (TDXd) in patients with metastatic disease to the brain: Study in Progress
Abstract PO5-07-11: Use of 64Cu-DOTA trastuzumab -PET to predict response to trastuzumab-deruxtecan (TDXd) in patients with metastatic disease to the brain: Study in Progress
Abstract
Background: We have utilized 64Cu-DOTA trastuzumab-PET imaging in patients with advanced breast cancer. In our experience, uptake on 64Cu-DOTA trastuzumab-P...
Abstract 1821: HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer
Abstract 1821: HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer
Abstract
Background: Trastuzumab is a standard therapy for HER2-positive breast cancer patients. Majority of the patients treated with trastuzumab in metastatic dise...
Abstract 2130A: Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models
Abstract 2130A: Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models
Abstract
Introduction: The major clinical problem for HER2 breast cancer target therapies is the acquisition of resistance. Trastuzumab has been used for the treatme...
Characteristics of HER2 3+ metastatic breast cancer patients with long-term benefit of trastuzumab.
Characteristics of HER2 3+ metastatic breast cancer patients with long-term benefit of trastuzumab.
e12523 Background: Because there is no cumulative dose, trastuzumab could be given until disease progression. However, characteristics of patients with long term benefit of trastu...
Abstract 1530: Trastuzumab treatment induces ADAM17 and HER ligands in vivo
Abstract 1530: Trastuzumab treatment induces ADAM17 and HER ligands in vivo
Abstract
Anti-HER2 monoclonal antibody trastuzumab is used as treatment in patients with HER2 positive breast cancer. However, resistance inevitably occurs for all r...
Analysis of Related Risk Factors and Prognostic Factors of Gastric Cancer with Bone Metastasis: A SEER-Based Study
Analysis of Related Risk Factors and Prognostic Factors of Gastric Cancer with Bone Metastasis: A SEER-Based Study
Background. Gastric cancer is among the most common malignant tumors at home and abroad, because its early symptoms are mostly insidious, which leads to distant metastasis when gas...
Aquaporin 3 Expression Pattern in Gastric Diseases and its significance
Aquaporin 3 Expression Pattern in Gastric Diseases and its significance
Abstract
Background
Aquaporin 3(AQP3) has been implicated in gastric intestinal metaplasia and gastric cancer, and considered as a biomarker to improve treatment strategy....

